TG Therapeutics
Commercializes BRIUMVI while developing B-cell therapies for immune-mediated diseases.
$53.93
After-hours close+0.02 (+0.04%)
At close$53.91(−3.25%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.36 | — | — |
| Aug 2026 | $0.31 | $0.05 | −83.6% |
| May 2026 | $0.23 | $0.17 | −26.1% |
| Feb 2026 | $0.35 | $0.14 | −60.0% |
| Nov 2025 | $0.24 | $2.43 | +912.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | $0.36 | — | — | $247.1M | — | — |
| Aug 3, 2026 | $0.31 | $0.05 | −83.6% | $229.8M | $240.3M | +4.6% |
| May 6, 2026 | $0.23 | $0.17 | −26.1% | $200.3M | $204.9M | +2.3% |
| Feb 26, 2026 | $0.35 | $0.14 | −60.0% | $191.8M | $192.6M | +0.4% |
| Nov 3, 2025 | $0.24 | $2.43 | +912.5% | $193.8M | $161.7M | −16.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 4, 2025 | ||||||
| May 5, 2025 | ||||||
| Mar 3, 2025 | ||||||
| Nov 4, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 1, 2024 | ||||||
| Feb 28, 2024 | ||||||
| Nov 1, 2023 | ||||||
| Aug 1, 2023 | ||||||
| May 1, 2023 | ||||||
| Feb 28, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 8, 2022 | ||||||
| May 10, 2022 | ||||||
| Mar 1, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 2, 2021 | ||||||
| May 10, 2021 | ||||||
| Mar 2, 2021 | ||||||
| Nov 9, 2020 | ||||||
| Aug 10, 2020 | ||||||
| May 11, 2020 | ||||||
| Mar 3, 2020 | ||||||
| Nov 12, 2019 | ||||||
| Aug 9, 2019 | ||||||
| May 10, 2019 | ||||||
| Mar 1, 2019 | ||||||
| Nov 9, 2018 | ||||||
| Aug 7, 2018 | ||||||
| May 8, 2018 | ||||||
| Mar 8, 2018 | ||||||
| Nov 8, 2017 | ||||||
| Aug 9, 2017 | ||||||
| May 5, 2017 | ||||||
| Mar 10, 2017 | ||||||
| Nov 7, 2016 | ||||||
| Aug 8, 2016 | ||||||
| May 10, 2016 | ||||||
| Mar 7, 2016 | ||||||
| Nov 9, 2015 | ||||||
| Aug 10, 2015 | ||||||